Business Wire

Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings

4.11.2024 21:50:00 EET | Business Wire | Press release

Share

ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/

Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire)

“Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.

Global Pharmacovigilance Expertise

Shelley Gandhi brings more than three decades of global PV and risk management experience to her role at ELIQUENT. Her extensive professional background includes more than 19 years of service at the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). During her tenure, Shelley served in multiple senior positions where she gained extensive knowledge of all European regulatory processes relating to monitoring the safety of licensed medicinal products and ancillary devices.

Shelley’s distinguished MHRA career included a role as the UK representative on the European Medicines Agency’s (EMA) EudraVigilance Expert Working Group. In this capacity, Shelley was instrumental in shaping EMA’s system for managing and analyzing information on suspected adverse reactions to medicines. Her contributions further enhanced key PV processes and systems across Europe.

Prior to joining ELIQUENT, Shelley served for more than 12 years as a strategic PV advisor to clients building and managing risk management systems. Shelley provided support to biotechnology clients across a broad range of therapeutic areas. Her experience includes strategic and technical advisory services in multiple markets from early clinical development to launch readiness.

At ELIQUENT, Shelley works with clients to ensure compliance with global safety standards, while anticipating changes, and preparing proactive solutions. Her deep understanding of drug safety and risk management protocols, coupled with her regulatory and industry experiences, amplifies ELIQUENT’s expanded PV and Risk Management Solutions. Learn more about Shelley.

Pharmacovigilance & Post-Market Surveillance Solutions

ELIQUENT’s expanded PV and Risk Management Solutions optimize practices to ensure consistency, compliance and operational efficiency across diverse markets. With decades of experience developed as leaders in both the public and private sectors, ELIQUENT’s industry-recognized PV experts support innovators with precision and expertise - enabling clients to confidently navigate global post-marketing surveillance, adverse event reporting, and risk management planning. Because there is no one-size-fits-all approach, each solution is built to support regulatory objectives, while aligning with evolving global demands. ELIQUENT’s customized global Pharmacovigilance & Risk Management Solutions include:

  • Global Support: Trusted guidance when navigating and complying with global PV regulations
  • Adverse Event Reporting: Systematic identification, objective analysis, and strategic guidance responding to unintended occurrences
  • Regulatory Reporting: Technical skill and institutional knowledge of complex regulatory reporting obligations
  • Signal Detection: Expert development and implementation of detection processes, including reporting and risk communication
  • Risk Assessment & Management: Proactive identification, assessment and planning to manage potential risk and ensure regulatory compliance
  • Post-Marketing Surveillance: Established network experts to support commercial product safety systems and reporting function
  • Risk Communications: Strategic development of communications plans to address emerging safety concerns and instill confidence in the market
  • Clinical Trials Safety Oversight: On-demand resources to support safety monitoring before and after regulatory approval
  • Qualified Person for Pharmacovigilance (QPPV): Comprehensive QPPV solutions ensure clients meet EU, UK, and regional pharmacovigilance requirements, while safeguarding patient safety.
  • Global PV Training: Bespoke pharmacovigilance training programs to uphold the highest regulatory standards across diverse global markets.

Integrated Solutions – Full-Service Support

ELIQUENT redefines regulatory consulting with a full-service platform that delivers integrated solutions across the product lifecycle. The firm's unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards. ELIQUENT's integrated platform of regulatory solutions feature the following integrated service offerings:

  • Regulatory Affairs Solutions: From the earliest phases of innovation through regulatory submissions, to post- approval support, ELIQUENT guides companies to approval and beyond.
  • Pharmacovigilance & Risk Management Solutions: With an approach that includes both strategic direction and hands-on global support, customized PV solutions empower companies to operate with confidence.
  • Quality & Compliance Solutions: Highly specialized compliance experts build customized solutions that equip companies with best- in-class strategic support, technical expertise, and project-based solutions.
  • Remediations Solutions: Respected professionals and global experts bring an unmatched level of credibility and trust when interacting with regulators and guiding companies to remediation solutions.
  • Talent Solutions: Whether you need a team of one or 100+, ELIQUENT’s talent solutions gives clients the ability to rapidly scale teams to the right size, with the right level of expertise, in the right locations.

About ELIQUENT Life Sciences

ELIQUENT Life Sciences is the fusion of six global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC. ­­ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.

Learn more about ELIQUENT Life Sciences at eliquent.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104361511/en/

Contacts

Taryn Fritz Walpole
twalpole@eliquent.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 11:05:00 EEST | Press release

In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-government agreement, funded under the European Union’s SAFE programme, underlines the high level of partnership between France and Romania. The first delivery is expected in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724603527/en/ The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200MM/A) radars to protect the Romanian airspace. The GM200 MM/A is a combat-proven medium-range 4D AESA radar, already deployed

Comsysto Reply Supports Audi in Evolving Its B2B Used Car Platform With an AI-Based Multi-Agent System24.7.2026 11:00:00 EEST | Press release

Comsysto Reply, the Reply Group company specialised in agile software development and cloud-native solutions, has partnered with Audi on the ongoing development of its “Used Car Platform”, the company’s central digital marketplace for B2B used car trading. A tailored multi-agent solution accelerates software development, reduces repetitive activities, and enables faster delivery of new features. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724143396/en/ Comsysto Reply, the Reply Group company specialised in agile software development and cloud-native solutions, has partnered with Audi in evolving its digital marketplace for B2B used car trading with an AI-based multi-agent system The platform represents a key digital sales channel for Audi’s used car sector. Since 2025, it has accounted for nearly 100% of the car manufacturer's B2B business. Building on this operational relevance, Audi and Comsysto Reply have introduced

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results24.7.2026 10:20:00 EEST | Press release

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the second quarter and first half of fiscal year 2026. “We delivered solid first-half 2026 results, achieving 6% growth year-over-year. This performance demonstrates the resilience of our biosimilar portfolio in the global market," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We remain confident in our growth trajectory; increasing product demand in Europe and the US is expected to be reflected sequentially in the second-half results, which would result in steady business performance for the fiscal year.” Second Quarter and First Half 2026 Results – Samsung Bioepis Samsung Bioepis, a 100% owned subsidiary of Samsung Epis Holdings, recorded revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026. This represents an increase of 45.5 bil

Ant International’s Alipay+ Adds New Bank Partners Amid Cross-border Mobile Payment Boom in Asia Pacific24.7.2026 07:10:00 EEST | Press release

Alipay+, Ant International's unified wallet gateway, is adding more bank partners to its network of over 50 leading digital wallets and financial institutions. Its global bank partners range from incumbent banks to fully digital banks. The latest banking partner to join Alipay+ is Hang Seng Bank, Alipay+’s first banking partner in Hong Kong. Hang Seng Mobile App users can now make payments via QR code scan in the Chinese Mainland and overseas by simply using the Hang Seng Mobile App at over 100 million merchants across more than 55 countries/regions. Accelerating revenue growth through cross-border mobile payments Demand for outbound cross-border payments from Asia Pacific is projected to increase faster than the global average. Alongside growing adoption of digital wallets, consumer-to-consumer (C2C) and consumer-to-business (C2B) outbound cross-border payment volume from Asia Pacific could reach 3.7 trillion by 2032, almost doubling from 2024. This growth represents opportunities for

mimik Operationalizes Agentic AI on the AMD Ryzen™ AI Embedded X100 Series23.7.2026 21:30:00 EEST | Press release

mimik today announced mimOE™ Embedded Edition, a package of its Agentix Operating Engine and a set of purpose-built tools for the AMD Ryzen™ AI Embedded X100 Series processor, the newest processor in a family designed for physical AI, autonomous systems, and industrial automation. Available to download today, mimOE Embedded Edition gives OEMs, tier-1 suppliers, system integrators, and agent developers the path to operationalize Agentix-Native systems (aka Agentic AI), in which autonomous agents can reason, coordinate, and act directly on devices, from PoC to scaled operations with certainty. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723555565/en/ Agentic AI operations are both CPU and GPU bound. Enterprises can now scale with certainty. Generative AI has centered on the GPU. Agentix-Native systems must spread the work. In a real multi-agent workflow traced by mimik, more than 80 percent of operations were CPU work: d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye